190 related articles for article (PubMed ID: 38260385)
1. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
Res Sq; 2024 Jan; ():. PubMed ID: 38260385
[TBL] [Abstract][Full Text] [Related]
2. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
3. Belantamab mafodotin for the treatment of multiple myeloma.
Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
[TBL] [Abstract][Full Text] [Related]
4. HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells.
Figueroa-Vazquez V; Ko J; Breunig C; Baumann A; Giesen N; Pálfi A; Müller C; Lutz C; Hechler T; Kulke M; Müller-Tidow C; Krämer A; Goldschmidt H; Pahl A; Raab MS
Mol Cancer Ther; 2021 Feb; 20(2):367-378. PubMed ID: 33298585
[TBL] [Abstract][Full Text] [Related]
5. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Becnel MR; Lee HC
Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
[TBL] [Abstract][Full Text] [Related]
6. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
7. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
8. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
9. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Morè S; Offidani M; Corvatta L; Petrucci MT; Fazio F
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296910
[TBL] [Abstract][Full Text] [Related]
10. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
Springer C; Krauter J; Trummer A
Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
[TBL] [Abstract][Full Text] [Related]
12. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
Acta Haematol; 2021 Nov; ():. PubMed ID: 34839282
[TBL] [Abstract][Full Text] [Related]
13. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
[TBL] [Abstract][Full Text] [Related]
14. Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma.
Ketchum EB; Clarke A; Clemmons AB
J Adv Pract Oncol; 2022 Jan; 13(1):77-85. PubMed ID: 35173991
[TBL] [Abstract][Full Text] [Related]
15. TP53 loss creates therapeutic vulnerability in colorectal cancer.
Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
[TBL] [Abstract][Full Text] [Related]
16. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
Abramson HN
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
[TBL] [Abstract][Full Text] [Related]
17. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses
Montes de Oca R; Alavi AS; Vitali N; Bhattacharya S; Blackwell C; Patel K; Seestaller-Wehr L; Kaczynski H; Shi H; Dobrzynski E; Obert L; Tsvetkov L; Cooper DC; Jackson H; Bojczuk P; Forveille S; Kepp O; Sauvat A; Kroemer G; Creighton-Gutteridge M; Yang J; Hopson C; Yanamandra N; Shelton C; Mayes P; Opalinska J; Barnette M; Srinivasan R; Smothers J; Hoos A
Mol Cancer Ther; 2021 Oct; 20(10):1941-1955. PubMed ID: 34253590
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
[TBL] [Abstract][Full Text] [Related]
19. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
Sheikh S; Lebel E; Trudel S
Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
[TBL] [Abstract][Full Text] [Related]
20. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]